Skip to search formSkip to main contentSkip to account menu

R 125489

Known as: R-125489, R125489 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (1)

Zanamivir
analogs & derivatives

Narrower (2)

laninamivirlaninamivir octanoate

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2011
Highly Cited
2011
Neuraminidase inhibitor R-125489--a promising drug for treating influenza virus: steered molecular dynamics approach.
Highly Cited
2010
Highly Cited
2010
Comprehensive assessment of 2009 Pandemic Influenza a (H1N1) Virus Drug Susceptibility in vitro
Background Antiviral drugs are an important option for managing infections caused by influenza viruses. This study assessed the… 
Highly Cited
2010
Highly Cited
2010
Laninamivir Prodrug CS-8958, a Long-Acting Neuraminidase Inhibitor, Shows Superior Anti-Influenza Virus Activity after a Single Administration
ABSTRACT Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for use… 
Review
2010
Review
2010
Laninamivir and its Prodrug, CS-8958: Long-Acting Neuraminidase Inhibitors for the Treatment of Influenza
  • M. Yamashita
  • Antiviral chemistry & chemotherapy
  • 2010
  • Corpus ID: 6155646
Oseltamivir and zanamivir are currently licensed worldwide for influenza treatment and chemoprophylaxis. Both drugs require twice… 
Highly Cited
2010
Highly Cited
2010
Assessment of Pandemic and Seasonal Influenza A (H1N1) Virus Susceptibility to Neuraminidase Inhibitors in Three Enzyme Activity Inhibition Assays
ABSTRACT The neuraminidase inhibitors (NAIs) zanamivir and oseltamivir are currently the only antiviral drugs effective for the… 
Highly Cited
2010
Highly Cited
2010
Efficacy of the New Neuraminidase Inhibitor CS-8958 against H5N1 Influenza Viruses
Currently, two neuraminidase (NA) inhibitors, oseltamivir and zanamivir, which must be administrated twice daily for 5 days for… 
2010
2010
Pharmacokinetics and disposition of CS-8958, a long-acting prodrug of the novel neuraminidase inhibitor laninamivir in rats
CS-8958, a prodrug of laninamivir (R-125489), is currently under development as an inhaled anti-influenza drug. In this study… 
Highly Cited
2009
Highly Cited
2009
CS-8958, a Prodrug of the Novel Neuraminidase Inhibitor R-125489, Demonstrates a Favorable Long-Retention Profile in the Mouse Respiratory Tract
ABSTRACT CS-8958 is a prodrug of the pharmacologically active form R-125489, a selective neuraminidase inhibitor, and has long… 
Highly Cited
2008
Highly Cited
2008
CS-8958, a Prodrug of the New Neuraminidase Inhibitor R-125489, Shows Long-Acting Anti-Influenza Virus Activity
ABSTRACT Two neuraminidase (NA) inhibitors, zanamivir (Relenza) and oseltamivir phosphate (Tamiflu), have been licensed for the… 
2004
2004
R-118958, a unique anti-influenza agent showing high efficacy for both prophylaxis and treatment after a single administration: from the in vitro stage to phase I study
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License